Head-To-Head Comparison: IceCure Medical (NASDAQ:ICCM) vs. Neovasc (NASDAQ:NVCN)

Neovasc (NASDAQ:NVCNGet Rating) and IceCure Medical (NASDAQ:ICCMGet Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.


This table compares Neovasc and IceCure Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neovasc -1,077.37% -78.98% -56.59%
IceCure Medical -462.46% -77.00% -61.72%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Neovasc and IceCure Medical, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neovasc 0 2 0 0 2.00
IceCure Medical 0 0 2 0 3.00

IceCure Medical has a consensus price target of $4.38, suggesting a potential upside of 285.46%. Given IceCure Medical’s stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than Neovasc.

Institutional and Insider Ownership

1.6% of Neovasc shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Neovasc has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500.

Earnings and Valuation

This table compares Neovasc and IceCure Medical’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neovasc $2.55 million 31.43 -$24.89 million ($12.29) -2.38
IceCure Medical $4.14 million 12.51 -$9.90 million ($0.45) -2.52

IceCure Medical has higher revenue and earnings than Neovasc. IceCure Medical is trading at a lower price-to-earnings ratio than Neovasc, indicating that it is currently the more affordable of the two stocks.


IceCure Medical beats Neovasc on 9 of the 14 factors compared between the two stocks.

About Neovasc

(Get Rating)

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.

About IceCure Medical

(Get Rating)

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.